Recurrent Lymphoma

The term recurrent lymphoma refers to a lymphoma that returns after it has been treated.

A recurrent lymphoma does not have to return to the same site of the body or be the exact same subtype in order to be considered a recurrent lymphoma. In fact, a recurrent lymphoma may return in parts of the body beyond the lymph system, and it's possible that lymphomas that were originally aggressive can be recurrent as indolent lymphomas, and originally indolent lymphomas can recur as aggressive ones.

Treatment of Recurrent Lymphoma

Treatment for recurrent lymphoma depends upon the subtype of lymphoma that has recurred.

For indolent, recurrent non-Hodgkin's lymphomas, treatment options will vary and will depend on the patient's individual disease and the judgment of the patient's oncology team, but it may include:

  • Combination chemotherapy
  • Radiotherapy (RT)
  • Radioimmunotherapy (RIT)
  • Monoclonal antibody maintenance therapy
  • An appropriate clinical trial, involving combination chemotherapy, RT, RIT, or other experimental drug or procedure.

For aggressive recurrent lymphoma that remain aggressive, treatment can be expected to be more aggressive:

  • Salvage combination chemotherapy
  • Autologuous or allogenic stem cell transplantation
  • Recommendation for an appropriate clinical trial

This does not represent the entirety of the options available to patients with recurrent lymphoma. Patients should discuss this with their physicians and together explore all the options available to them.

Sources

Mayo Clinic
Lymphoma Information Network

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap